ALNY Overview
Upcoming Projects (ALNY)
-
Alnylam’s AMVUTTRA (Vutrisiran) in ATTR Amyloidosis: Cardiomyopathy & Polyneuropathy Market Outlook
Ticker: ALNY
Execute By: Dec 30, 2025
Executed Projects (ALNY)
-
A second look: Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: ALNY, BBIO, PFE
Executed On: Apr 16, 2025 at 12:00 PM EDT -
Discussing the expanded label for Amvuttra, and commercial outlook for Amvuttra, Vyndaqel and Attruby in Transthyretin amyloid cardiomyopathy (ATTR-CM)
Tickers: ALNY, BBIO, PFE
Executed On: Apr 01, 2025 at 03:00 PM EDT -
Two Week Delay: Survey on ATTR-CM and BBIO-ALNY-PFE Market Dynamic February 2025
Tickers: ALNY, BBIO, PFE
Executed On: Mar 19, 2025 at 09:41 AM EDT -
Examining the potential of Intella's nexiguran ziclumeran (nex-z) and Alnylam's nucresiran in treating Transthyretin (ATTR) Amyloidosis
Tickers: NTLA, ALNY
Executed On: Jan 08, 2025 at 09:00 AM EST -
Revisiting the HELIOS-B data for vutrisiran in ATTR-CM following publication in NEJM and presentation at ESC
Ticker: ALNY
Executed On: Sep 03, 2024 at 04:30 PM EDT -
A Second Look: Digging into Alnylam's recent topline vutrisiran data from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)
Ticker: ALNY
Executed On: Jul 25, 2024 at 02:00 PM EDT -
Digging into Alnylam's recent topline vutrisiran data from the HELIOS-B Phase 3 study in patients with ATTR amyloidosis with cardiomyopathy (ATTR-CM)
Ticker: ALNY
Executed On: Jul 15, 2024 at 02:00 PM EDT -
Deciphering the HELIOS-B Trial: Discussing Alnylam's Vutrisiran in ATTR-Cardiomyopathy
Ticker: ALNY
Executed On: Apr 22, 2024 at 02:00 PM EDT -
Delving into Alnylam Pharmaceuticals, Inc.'s Zilebesiran (ALN-AGT) for the Treatment of Hypertension: Insights from the KARDIA-2 Phase 2 Study
Ticker: ALNY
Executed On: Apr 17, 2024 at 01:15 PM EDT -
Digging into Alnylam APOLLO-B Phase 3 study results of patisiran in ATTR and recent FDA CRL
Ticker: ALNY
Executed On: Oct 26, 2023 at 06:00 PM EDT -
Evaluating Alnylam Pharmaceuticals' Zilebesiran (ALN-AGT) for Hypertension
Ticker: ALNY
Executed On: Sep 13, 2023 at 12:00 PM EDT -
An updated look at the results from the ATTRibute-CM trial of Acoramidis in patients with transthyretin amyloid cardiomyopathy
Tickers: BBIO, PFE, ALNY
Executed On: Sep 06, 2023 at 10:30 AM EDT -
Discussing the ATTRibute Part B results on Acoramidis for patients with ATTR cardiomyopathy.
Tickers: BBIO, PFE, ALNY
Executed On: Jul 20, 2023 at 09:00 AM EDT -
A Third View: Discussing acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 12, 2023 at 01:00 PM EDT -
A Second View: A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy)
Tickers: BBIO, PFE, ALNY
Executed On: Jul 11, 2023 at 01:30 PM EDT -
A discussion of acoramidis and part B of the ATTRibute trial in ATTR-CM (Transthyretin Amyloid Cardiomyopathy).
Tickers: BBIO, PFE, ALNY
Executed On: Jul 07, 2023 at 01:00 PM EDT -
A Second Opinion: Discussing the Topline Results from Alnylam's APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 10, 2022 at 03:00 PM EDT -
Discussing the Topline Results from Alnylam's APOLLO-B Phase 3 Study of Patisiran in Patients with ATTR Amyloidosis with Cardiomyopathy
Ticker: ALNY
Executed On: Aug 09, 2022 at 03:00 PM EDT -
A look at patisiran ahead of the APOLLO-B readout
Ticker: ALNY
Executed On: May 31, 2022 at 03:00 PM EDT -
Examining Alnylam's pipeline in treating cardiac amyloidosis
Ticker: ALNY
Executed On: Mar 24, 2022 at 02:00 PM EDT
Expired Projects (ALNY)
-
Digging into Alnylam’s recently approved Oxlumo in primary hyperoxaluria
Ticker: ALNY
Execute By: Nov 30, 2022 -
Discussing Alnylam’s Lumasiran in primary hyperoxaluria type 1
Ticker: ALNY
Execute By: Jun 30, 2022
Upcoming & Overdue Catalysts (ALNY)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (ALNY)
-
Alnylam (ALNY) Initiates APOLLO-B Phase 3 Study of Patisiran for the Treatment of Transthyretin Amyloidosis with Cardiomyopathy
Ticker: ALNY
Occurred on: Sep 16, 2019 -
Silence Therapeutics (SLN) Sues Alnylam (ALNY) on dispute over commercialization of ONPATTRO (patisiran) in the EU
Tickers: ALNY, IONS, SLN.L, AKCA
Occurred on: Oct 11, 2018 -
NDA of Patisiran for Familial Amyloidotic Polyneuropathy in patients with ATTR to be filed late 2017, assuming positive data
Ticker: ALNY
Occurred on: Nov 16, 2017 -
Phase 3 data due of Patisiran APOLLO trial for Familial Amyloidotic Polyneuropathy in Patients with ATTR due in Mid-2017
Ticker: ALNY
Occurred on: Sep 20, 2017 -
Start of Phase 3 Givosiran study expected in late 2017
Ticker: ALNY
Occurred on: Sep 07, 2017 -
New, One-Year Data from ORION-1 Phase II Study of Inclisiran Affirms Dose for Phase III Trials
Ticker: ALNY
Occurred on: Aug 28, 2017 -
Givosiran Additional data release from Phase 1 anticipated in mid-2017
Ticker: ALNY
Occurred on: Jun 26, 2017 -
Phase 3 Studies of Inclisiran for Hypercholesterolemia Expected to Start in the First Half of 2017
Ticker: ALNY
Occurred on: Apr 26, 2017 -
Phase 2 36-month OLE data of Patisiran in hATTR Patients with Polyneuropathy expected in late 2017
Ticker: ALNY
Occurred on: Apr 26, 2017 -
BPC of Patisiran estimate mid 2017 for data release
Ticker: ALNY
Occurred on: Apr 26, 2017 -
Alnylam Presents New Data on Fitusiran at EAHAD
Ticker: ALNY
Occurred on: Feb 02, 2017 -
Alnylam to File an IND for ALN-HBV in early 2016
Ticker: ALNY
Occurred on: Jan 09, 2017 -
Phase 2 data of Inclisiran for Hypercholesterolemia Expected in early 2017
Ticker: ALNY
Occurred on: Jan 08, 2017 -
If the Phase 1/2 study results of ALN-CC5 are positive, Alnylam expects to initiate a Phase 3 trial in 2017
Ticker: ALNY
Occurred on: Dec 05, 2016 -
Fitusiran (ALN-AT3) Phase 1 Open Label Extension study initial data expected in late 2016
Ticker: ALNY
Occurred on: Dec 03, 2016 -
Initial data from the ORION-1 Phase 2 study on ALN-PCSsc are expected to be presented by The Medicines Company (MDCO) on November 15, 2016
Tickers: ALNY, MDCO
Occurred on: Nov 15, 2016 -
Phase 3 data of Revusiran ENDEAVOUR trial for ATTR in patients with familial amyloidotic cardiomyopathy (FAC) due 2018
Ticker: ALNY
Occurred on: Oct 05, 2016 -
Initial Phase 1 clinical data for ALN-GO1 in treating Primary Hyperoxaluria Type 1 will be presented in late 2016
Ticker: ALNY
Occurred on: Sep 24, 2016 -
24-month data from the Phase 2 Open-Label Extension (OLE) study with patisiran to be released in mid-2016
Ticker: ALNY
Occurred on: Jan 11, 2016
Strategic Initiatives (ALNY)
-
Sanofi (SNY) and Alnylam (ALNY) Agree to Co-Develop and Commercialize RNAi Therapeutic Fitusiran in Treatment of Hemophilia and Rare Bleeding Disorders
Tickers: ALNY, SNY
Announcement Date: Nov 14, 2016
